Shire plc Director/PDMR Shareholding

 
TIDMSHP 
 
Director/PDMR Shareholding 
 
February 17, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") 
 
Notification of transactions by person discharging managerial responsibilities 
 
1.   Details of the person discharging managerial responsibilities 
     ("PDMR") / person closely associated with them ("PCA") 
 
a)   Name              Kim Stratton 
 
2.   Reason for the notification 
 
a)   Position / status Head of International Commercial - PDMR 
 
b)   Initial           Amendment to prior notification to include the 
     notification /    automatic disposal of Ordinary Shares, as omitted 
     amendment         from the initial notification due to a 
                       transcription error, related to the automatic 
                       exercise of an option as detailed in the initial 
                       notification. 
 
3.   Details of the issuer, emission allowance participant, auction 
     platform, auctioneer or auction monitor 
 
a)   Name              Shire plc 
 
b)   LEI               54930005LQRLI2UXRQ59 
 
4.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc Ordinary Shares of 5 pence each 
     the financial     ("Ordinary Shares") 
     instrument, type 
     of instrument 
 
     Identification    ISIN: JE00B2QKY057 
     code 
 
b)   Nature of the     Automatic exercise of option over notional 
     transaction       Ordinary Shares granted under the Shire Global 
                       Employee Stock Purchase Plan on November 1, 2015, 
                       and consequent receipt of Ordinary Shares. 
 
c)   Price(s) and              Price(s)                 Volume(s) 
     volume(s) 
                                GBP40.70                     244 
 
d)   Aggregated        N/A (single transaction) 
     information 
 
e)   Date of the       October 31, 2016 
     transaction 
 
f)   Place of the      N/A 
     transaction 
 
5.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc Ordinary Shares of 5 pence each 
     the financial     ("Ordinary Shares") 
     instrument, type 
     of instrument 
 
     Identification    ISIN: JE00B2QKY057 
     code 
 
b)   Nature of the     Automatic disposal of Ordinary Shares related to 
     transaction       the automatic option exercise referenced in 
                       section 4. above. The proceeds of this disposal 
                       were used to satisfy personal tax liabilities 
                       arising from the option exercise. 
 
c)   Price(s) and              Price(s)                 Volume(s) 
     volume(s) 
                                GBP46.07                      9 
 
d)   Aggregated        N/A (single transaction) 
     information 
 
e)   Date of the       October 31, 2016 
     transaction 
 
f)   Place of the      London Stock Exchange (XLON) 
     transaction 
 
Oliver Strawbridge 
 
Senior Assistant Company Secretary 
 
For further information please contact: 
 
Investor Relations 
 
Ian Karp                        [e-mail]            [phone] 
 
Robert Coates                   [e-mail]          [phone] 
 
Media 
 
Lisa Adler                      [e-mail]       [phone] 
 
Debbi Ford                      [e-mail]       [phone] 
 
NOTES TO EDITORS 
 
About Shire 
 
Shire is the leading global biotechnology company focused on serving people 
with rare diseases. We strive to develop best-in-class products, many of which 
are available in more than 100 countries, across core therapeutic areas 
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage 
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary 
Angioedema; and a growing franchise in Oncology. 
 
Our employees come to work every day with a shared mission: to develop and 
deliver breakthrough therapies for the hundreds of millions of people in the 
world affected by rare diseases and other high-need conditions, and who lack 
effective therapies to live their lives to the fullest. 
 
www.shire.com 
 
 
 
END 
 

(END) Dow Jones Newswires

February 17, 2017 07:00 ET (12:00 GMT)